1. Home
  2. VIGL vs LICN Comparison

VIGL vs LICN Comparison

Compare VIGL & LICN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VIGL
  • LICN
  • Stock Information
  • Founded
  • VIGL 2020
  • LICN 2004
  • Country
  • VIGL United States
  • LICN China
  • Employees
  • VIGL N/A
  • LICN N/A
  • Industry
  • VIGL Biotechnology: Pharmaceutical Preparations
  • LICN
  • Sector
  • VIGL Health Care
  • LICN
  • Exchange
  • VIGL Nasdaq
  • LICN Nasdaq
  • Market Cap
  • VIGL 89.3M
  • LICN 8.7M
  • IPO Year
  • VIGL 2022
  • LICN 2023
  • Fundamental
  • Price
  • VIGL $2.71
  • LICN $0.08
  • Analyst Decision
  • VIGL Strong Buy
  • LICN
  • Analyst Count
  • VIGL 5
  • LICN 0
  • Target Price
  • VIGL $21.00
  • LICN N/A
  • AVG Volume (30 Days)
  • VIGL 2.6M
  • LICN 11.9M
  • Earning Date
  • VIGL 03-25-2025
  • LICN 12-31-2024
  • Dividend Yield
  • VIGL N/A
  • LICN N/A
  • EPS Growth
  • VIGL N/A
  • LICN 36.90
  • EPS
  • VIGL N/A
  • LICN 0.28
  • Revenue
  • VIGL N/A
  • LICN $41,929,000.00
  • Revenue This Year
  • VIGL N/A
  • LICN N/A
  • Revenue Next Year
  • VIGL N/A
  • LICN N/A
  • P/E Ratio
  • VIGL N/A
  • LICN $0.26
  • Revenue Growth
  • VIGL N/A
  • LICN 24.86
  • 52 Week Low
  • VIGL $1.49
  • LICN $0.06
  • 52 Week High
  • VIGL $6.06
  • LICN $2.44
  • Technical
  • Relative Strength Index (RSI)
  • VIGL 70.34
  • LICN 23.16
  • Support Level
  • VIGL $2.22
  • LICN $0.06
  • Resistance Level
  • VIGL $2.84
  • LICN $0.08
  • Average True Range (ATR)
  • VIGL 0.29
  • LICN 0.01
  • MACD
  • VIGL 0.08
  • LICN 0.03
  • Stochastic Oscillator
  • VIGL 78.60
  • LICN 18.63

About VIGL Vigil Neuroscience Inc.

Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.

About LICN Lichen China Limited

Lichen China Ltd is a holding company. The company, along with its subsidiaries provides financial and taxation solution services; education support services; and software and maintenance services. The company generates Majority revenue from Financial and taxation solution services.

Share on Social Networks: